Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.

ABSTRACT:

Background

Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first-line setting remain poorly defined.

Methods

We retrospectively reviewed charts for 85 adults with mRCC of any histology receiving combination of ICI/TKI in any line of treatment at two academic centers as of 05/01/2020. We collected clinical, pathological, and treatment-related variables. Outcomes including objective response rate (ORR), progression-free survival (PFS), and toxicity were analyzed via descriptive statistics and the Kaplan-Meier method.

Results

Patients received pembrolizumab, nivolumab, avelumab, or nivolumab-ipilimumab, with c

SUBMITTER: Yang Y 

PROVIDER: S-EPMC9385597 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature